Brazil halting coronavirus vaccine CoronaVac trial surprises the world
The potential vaccine is being developed by Chinese biopharmaceutical firm Sinovac and in Brazil would be mostly produced by Sao Paulo's state-run Butantan Institute
Brazil | Coronavirus Vaccine
AP | PTI
Last Updated at November 11, 2020 03:18 IST
Brazil's health regulator has halted clinical trials of the potential coronavirus vaccine CoronaVac, citing an “adverse, serious event.” The decision posted on Anvisa's website Monday night elicited immediate surprise from parties involved in producing the vaccine. The potential vaccine is being developed by Chinese biopharmaceutical firm Sinovac and in Brazil would be mostly produced by Sao Paulo's state-run Butantan Institute. Sao Paulo state's government said in a statement it “regrets being informed by the press and not directly by Anvisa, as normally occurs in clinical trials of this nature.” Butantan said in a statement that it was surprised by Anvisa's decision and that it would hold a news conference Tuesday. The CoronaVac shot has already stirred controversy in Brazil, where President Jair Bolsonaro has cast doubt on its prospective effectiveness. He sparked confusion last month when he publicly rejected it, saying Brazilians would not be used as guinea pigs.
Carson had spent Tuesday evening at the White House watching the election results come in. Another top aide to the president, David Bossie, was also at the White House event and tested positive on Sunday and has been self-isolating at home, NBC news said. Bossie, 55, was tapped a few days ago to lead the president's legal challenges to the election results. AFP
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
First Published: Wed, November 11 2020. 00:20 IST